Stason Industrial Corporation entered the U.S. generics market with the establishment of Stason Pharmaceuticals in 1994, and currently holds a portfolio of approved ANDAs.
Our portfolio offers generic pharmaceutical products, marketed through our global partners. These generic drugs are initially filed under an Abbreviated New Drug Application (ANDA) in the US or Abbreviated New Drug Submission (ANDS) in Canada. Our future generic development will continue to focus on those generics requiring high containment manufacturing, cytotoxic products, and difficult to manufacture drugs. We believe these qualities present an increased barrier to market entry of our competitors.
Our core generic, therapeutic categories include: oncology, CNS, cardiovascular, and dermatologic indications. Expanding our generic product portfolio, we are geared to file 2-3 ANDA’s or ANDS’s per year in the areas of oncology and CNS, and launch these products under various labels for different market segments to maximize market potential. To learn more about Our portfolio of generic drugs, please contact us at Info@stason.com.